 | | |  Good morning. Over the past few years, with interest rates at zero, investors settled into a style of investing known as TINA – short for "there is no alternative." It was an excuse to buy stocks, particularly ones posting the strongest growth, as they tend to rally the most in a bull market.
But times are changing. And investors are looking for alternatives. Bond yields still look low, even after bond prices have been crushed. And tech companies, even those still growing quickly right now, are hardly the store of value that they once were.
With inflation rising, even alternatives like gold and Bitcoin have been a poor store of value. Gold has been arguably flat, while Bitcoin has traded like a tech stock and gotten crushed. That's why investors should continue to look for downside trades like put options, and continue to hedge existing long-term positions with tools like covered call writing. There are some alternatives, just not a lot for today's markets.
Now here's the rest of the news: | | | | | | | | Invest In This Biotech Company Solving A $240B Problem | | | | | | Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These "band-aid" therapies are temporary and do not treat the root cause of osteoarthritis.
Enter Cytonics.
This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called "A2M," to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients' quality of life.
Backed by Johnson & Johnson and the NIH, Cytonics is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, "CYT-108," has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies.
Cytonics' first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public. | |
| | |  | DOW 29,888.78 | -0.13% | | |  | S&P 3,674.84 | +0.22% | | | | | NASDAQ 10,798.35 | +1.43% | | | | | *As of market close | | | • | Stocks traded mixed on Friday, with tech moving modestly higher. | | | • | Oil sank 6.4 percent, closing at $110.03 per barrel. | | | • | Gold dipped 0.5 percent, ending the day at $1,840 per ounce. | | | • | Cryptocurrencies were generally flat, with Bitcoin at $20,573 at the market close. | | | | | | | |
| | | Short-Term Fears Are Creating the Best Value for Tech in Years | | | | A bear market will take down most stocks, irrespective of how an individual company is performing. This creates a situation where investors can set themselves up to buy great companies at reasonable prices.
A great company can be an industry leader, or one that has some sort of competitive advantage or potential sources of growth. Whatever the reason, when markets recover, great companies tend to resume their long-term compounded growth over time.
» FULL STORY | | | | |
| | Insider Trading Report: NortonLifeLock (NLOK) | | | | Peter Feld, a director at NortonLifeLock (NLOK), recently picked up 2,500,000 shares. The buy increased his holdings by 15 percent, and came to a total price of $55.5 million.
This marks the first insider buy at the cyber safety solution company since the summer of 2019. Otherwise, company insiders, including both C-suite executives and directors, have been sellers of shares, irrespective of how shares have traded over the past three years.
» FULL STORY | | | | |
| | Unusual Options Activity: Nvidia (NVDA) | | | | Shares of graphics processing company Nvidia (NVDA) have been knocked down heavily from their highs, and are now down year-over-year. One trader sees a further decline in the coming weeks.
That's based on the July 22 $155 puts. With 32 days until expiration, 16,161 contracts traded compared to an open interest of 213, for a 76-fold rise in volume on the trade. The buyer of the puts paid $11.60 to get into the trade.
» FULL STORY | | | | |
| | • | Fed Remains Committed to Inflation Target
The Federal Reserve remains committed to returning inflation to its target level of 2 percent per year, according to chairman Jerome Powell. The Fed views that as a key part of its dual mandate to support both full employment and also price stability. | | | | • | In-Store Shopping on the Rise
As the pandemic has ended, consumers have returned to shopping in-store rather than just online. Part of the move may also be to avoid delivery and shipping fees, which have expanded in recent years. Others view it as a social activity. | | | | • | Stolen Goods Appearing Online
Large-scale robberies in retail stores are leading to a rise in reselling those goods online. Retailers noted that $68.9 billion in products were stolen last year. While arrests are on the rise for organized retail theft, so has the value of those stolen goods. | | | | • | Musk Seeks Active Role at Twitter
During Thursday's "all hands" meeting at Twitter (TWTR), potential buyer Elon Musk stated that he would want to be involved in the product. That would include providing input for the company on new features, as well as finding a way to better match the company's costs to its revenues. | | | | • | Florida Mansion Lists for $175 Million
An oceanfront property in Manalapan, Florida, is listing for $175 million. If sold, it would be the highest-priced sale in the state, far exceeding the current record near $130 million. The mansion was bought just one year ago for $94.2 million by internet entrepreneur Jim Clark. | | |
| | | | TOP | | | NCLH | 10.116% | | | | CCL | 9.714% | | | | ENPH | 8.936% | | | | SEDG | 8.438% | | | | AAL | 6.415% | | | | BOTTOM | | | FANG | 8.52% | | | | COP | 8.475% | | | | DVN | 8.298% | | | | PXD | 8.17% | | | | CTRA | 7.3% | | | | |
| | |  | | Let me tell you, we're in a recession. It's a mild recession. It's not an official recession by the NBER, certainly not yet, but this first half is negative GDP growth, and it's ending on a slide. | | - Jeremy Siegel, Wharton Business School professor, explaining his view on the economy and why the stock market may take some time to rise until economic conditions improve. | |
| | Invest In This Biotech Company Solving A $240B Problem | | | | | | Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These "band-aid" therapies are temporary and do not treat the root cause of osteoarthritis.
Enter Cytonics.
This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called "A2M," to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients' quality of life.
Backed by Johnson & Johnson and the NIH, Cytonics is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, "CYT-108," has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies.
Cytonics' first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public. | |
|
No comments:
Post a Comment